The promising role of placental growth factor in association with cyclooxygenase-2 as predictive markers for recurrent ovarian endometriosis

Yomna Zamzam, Asmaa Bedeer, Aymen M. El-Saka, Yosra Abdelmonem Zamzam, Ayman El-Dorf
In: Egyptian Journal of Pathology · 2017 · vol. 37(2) , pp. 333–338 · doi:10.1097/01.xej.0000527744.26306 · W2793612418
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

Placental growth factor (PlGF) and cyclooxygenase-2 (COX-2) overexpression were found to be significantly associated with recurrent ovarian endometriosis in this study.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-27 · read from full text ⓘ

This study investigated whether serum placental growth factor (PlGF) and cyclooxygenase-2 (COX-2) expression could serve as predictive markers for the recurrence of ovarian endometriosis. The researchers analyzed blood samples and histopathological specimens from 88 patients confirmed to have the condition, assessing levels of PlGF and COX-2 postoperatively. Results indicated a statistically significant association between higher serum PlGF levels, COX-2 overexpression, and subsequent disease recurrence. Although these findings suggest potential utility in predicting outcomes, the authors note that further studies are required to validate serum PlGF as a reliable screening tool. This paper is centrally about endometriosis — specifically focusing on biomarkers for recurrent ovarian endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objective Various risk factors, both patient dependent and surgeon dependent, have been involved in the recurrence of ovarian endometriosis. Identification of an ideal biomarker to predict the recurrence of ovarian endometriosis is essential for a proper treatment plan, as it could allow the use of targeted therapy to postpone or even prevent recurrence altogether and prevent unnecessary medication, thus attaining effectiveness and diminishing healthcare costs. Patients and methods In all, 95 suspected patients with ovarian endometriosis, who were admitted to Tanta Gynecology and Obstetrics Department for laparoscopy or laparotomy from June 2014 to June 2017, were included in the study. Blood samples for serum placental growth factor (PlGF) tests were taken from patients at the time of admission. Postoperatively, all specimens were subjected to histopathological evaluation in the Tanta Pathology Department; 88 of 95 patients were confirmed to have endometriosis. Afterwards, the diagnosed cases were immunostained for both PlGF and cyclooxygenase-2 (COX-2). Results There was a statistically significant relation between PlGF, COX-2 overexpression, high PlGF serum level, and the disease recurrence in the studied cases ( P <0.01, 0.025, and <0.05, respectively). Conclusion The panel of PlGF and COX-2 holds a promise for ovarian endometriosis: as a predictive marker for recurrence and as a potential therapeutic target. Our current analysis provides a link between high PlGF serum levels and recurrence of ovarian endometriosis. However, still further studies are needed to establish the use of serum PlGF as a screening test for prediction of recurrence among women with ovarian endometriosis.
Full text 1,939 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Objective

Various risk factors, both patient dependent and surgeon dependent, have been involved in the recurrence of ovarian endometriosis. Identification of an ideal biomarker to predict the recurrence of ovarian endometriosis is essential for a proper treatment plan, as it could allow the use of targeted therapy to postpone or even prevent recurrence altogether and prevent unnecessary medication, thus attaining effectiveness and diminishing healthcare costs. Patients and methods In all, 95 suspected patients with ovarian endometriosis, who were admitted to Tanta Gynecology and Obstetrics Department for laparoscopy or laparotomy from June 2014 to June 2017, were included in the study. Blood samples for serum placental growth factor (PlGF) tests were taken from patients at the time of admission. Postoperatively, all specimens were subjected to histopathological evaluation in the Tanta Pathology Department; 88 of 95 patients were confirmed to have endometriosis. Afterwards, the diagnosed cases were immunostained for both PlGF and cyclooxygenase-2 (COX-2).

Results

There was a statistically significant relation between PlGF, COX-2 overexpression, high PlGF serum level, and the disease recurrence in the studied cases (P<0.01, 0.025, and <0.05, respectively).

Conclusion

The panel of PlGF and COX-2 holds a promise for ovarian endometriosis: as a predictive marker for recurrence and as a potential therapeutic target. Our current analysis provides a link between high PlGF serum levels and recurrence of ovarian endometriosis. However, still further studies are needed to establish the use of serum PlGF as a screening test for prediction of recurrence among women with ovarian endometriosis.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK